论文部分内容阅读
目的:探讨成人急性淋巴细胞白血病(ALL)细胞免疫表型特点及其对疗效的影响。方法:46例成人ALL初治患者,采用流式细胞术方法分析患者的免疫表型,然后给予标准诱导缓解方案(VDCLP方案)化疗,并观察其疗效。分析比较ALL伴髓系相关抗原(CD11b、CD13、CD14、CD15、CD33、CD117、cMPO)阳性患者与阴性患者之间的完全缓解(CR)率,HLA-DR表达情况及其与化疗后CR的关系。结果:46例ALL患者中,共有28例表达髓系相关抗原。伴髓系抗原表达阳性患者(My+ALL)CR率为78.6%,与伴髓系抗原表达阴性患者(My-ALL)CR率(83.3%)比较差异无统计学意义(P>0.05)。ALL患者HLA-DR+表达率为65.2%,HLADR+和HLA-DR-ALL患者CR率比较差异有统计学意义(70%∶100%,P<0.05)。结论:ALL患者无论有无髓系抗原的表达其疗效无显著差异,但HLA-DR表达则明显降低化疗后CR率。
Objective: To investigate the cellular phenotype of adult acute lymphoblastic leukemia (ALL) and its effect on the therapeutic effect. Methods: Forty-six patients with newly diagnosed adult ALL were enrolled. The immunophenotypes of the patients were analyzed by flow cytometry. Then the standard induction remission (VDCLP) regimen was given and the curative effect was observed. To compare and analyze the rate of complete remission (CR), the expression of HLA-DR between ALL patients with positive myeloid lineage associated antigen (CD11b, CD13, CD14, CD15, CD33, CD117, cMPO) relationship. RESULTS: Of the 46 ALL patients, a total of 28 patients expressed myeloid-associated antigens. The CR rate of myeloid antigen positive patients (My + ALL) was 78.6%, which was not significantly different from that of myeloid antigen negative patients (My-ALL) (83.3%) (P> 0.05). The rate of HLA-DR + expression in ALL patients was 65.2%. The CR rates in HLADR + and HLA-DR-ALL patients were significantly different (70% vs 100%, P <0.05). Conclusion: There is no significant difference in the efficacy of myeloid antigen expression in patients with ALL, but the expression of HLA-DR significantly reduces the post-chemotherapy CR rate.